Please assess the completion status of the following clinical trial:

Trial Title: Bevacizumab and Erlotinib Followed by Cisplatin or Carboplatin and Gemcitabine in Treating Patients With Newly Diagnosed or Recurrent Stage IIIB or Stage IV NSCLC

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically or cytologically confirmed non-squamous non-small cell lung cancer (NSCLC)~  * Newly diagnosed or recurrent disease~* Meets 1 of the following staging criteria:~  * Stage IIIB disease, meeting both of the following criteria:~    * Proven malignant effusion or supraclavicular node involvement (i.e., N3 supraclavicular nodes)~   * Not a candidate for curative multimodality treatment or surgery~ * Stage IV disease~* Measurable disease, defined as ≥ 1 lesion (outside of irradiated areas) that can be measured in ≥ 1 dimension as ≥ 10 mm by spiral or multi-slice CT scan or MRI~* Immediate chemotherapy not clinically mandatory in the judgement of the investigator~* No intrathoracic large, centrally located tumors and/or cavitary lesions invading or abutting major blood vessels~* No evidence of clinically active interstitial lung disease~  * Patients with chronic stable radiographic changes who are asymptomatic are eligible~* No small cell lung cancer (SCLC), squamous NSCLC, or combined SCLC-NSCLC tumors~* No brain metastases~PATIENT CHARACTERISTICS:~* WHO performance status 0-1~* Hemoglobin ≥ 10 g/dL~* Absolute neutrophil count ≥ 1,500/mm³~* Thrombocyte count ≥ 100,000/mm³~* Bilirubin ≤ 1.5 times upper limit of normal (ULN)~* ALT ≤ 2.5 times ULN (5 times ULN if liver metastases present)~* Alkaline phosphatase ≤ 2.5 times ULN (5 times ULN if bone metastases present)~* Quick ≥ 70% OR INR ≤ 1.5~* Creatinine ≤ 2.0 times ULN~* Proteinuria ≤ 2+ by urine dipstick~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception during and for 12 months after completion of study treatment~* Able to understand trial information given by the investigator and complete quality of life questionnaire~* No pre-existing condition that would preclude swallowing and/or absorption of oral medication~* No prior or concurrent malignancies, except for the following:~  * Malignancy for which the minimum relapse-free interval is ≥ 5 years~ * Nonmelanoma skin cancer or adequately treated carcinoma in situ of the cervix~* No other medical condition that would preclude study participation, including any of the following:~  * Unstable or uncompensated respiratory, cardiac, hepatic, or renal disease~ * Active infection~ * Uncontrolled diabetes mellitus~ * Hypertension ≥ 150/100 mm Hg despite treatment~ * Myocardial infarction within the past 3 months~ * History of hemorrhagic disorders~ * Non-healing wound, ulcer, or bone fracture~* No clinical history of coagulopathy or thrombosis~* No hemoptysis or hematemesis ≥ grade 2 (defined as bright red blood of ≥ 5 mL per episode) within the past 6 months~* No known hypersensitivity to study drug(s) or to any other component of the study drugs~* No significant traumatic injury within the past 28 days~* No serious underlying medical condition that would impair the ability of the patient to participate in the trial or that would preclude use of study drugs~* No cerebrovascular accident or other CNS bleeding within the past 6 months~PRIOR CONCURRENT THERAPY:~* At least 4 weeks since prior radiotherapy and recovered~  * No prior radiotherapy to lesion(s) selected for measurement~* No prior chemotherapy for advanced disease~  * At least 6 months since prior neoadjuvant or adjuvant systemic chemotherapy for NSCLC~ * Prior intrapleural or intrapericardial local chemotherapy allowed~* No prior endothelial growth factor and/or vascular endothelial growth factor (receptor)-targeted therapy for NSCLC~* More than 28 days since prior major surgical procedure or open biopsy~* More than 30 days since prior treatment in another clinical trial~* No concurrent anticoagulants (e.g., phenprocoumon, acenocoumarol, or full-dose warfarin or heparin)~* No concurrent full-dose continuous use of non-steroid anti-inflammatory drugs (NSAIDs)~* No concurrent aspirin or clopidogrel bisulfate~  * Low-dose aspirin (≤ 325 mg daily) may be continued in patients at high risk for arterial thromboembolic disease~* No other concurrent drugs contraindicated for use with the study drugs, according to the Swissmedic-approved product information~* No other concurrent experimental drugs or anticancer therapy, including chemotherapy, immunotherapy, or hormone therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete